152 related articles for article (PubMed ID: 18158573)
1. Factors influencing serum concentration of CA125 and CA15-3 in Iranian healthy postmenopausal women.
Dehaghani AS; Ghiam AF; Hosseini M; Mansouri S; Ghaderi A
Pathol Oncol Res; 2007; 13(4):360-4. PubMed ID: 18158573
[TBL] [Abstract][Full Text] [Related]
2. Racial/ethnic differences in average CA125 and CA15.3 values and its correlates among postmenopausal women in the USA.
Sasamoto N; Vitonis AF; Fichorova RN; Yamamoto HS; Terry KL; Cramer DW
Cancer Causes Control; 2021 Mar; 32(3):299-309. PubMed ID: 33462738
[TBL] [Abstract][Full Text] [Related]
3. The diagnostic value of serum tumor markers CEA, CA19-9, CA125, CA15-3, and TPS in metastatic breast cancer.
Wang W; Xu X; Tian B; Wang Y; Du L; Sun T; Shi Y; Zhao X; Jing J
Clin Chim Acta; 2017 Jul; 470():51-55. PubMed ID: 28457854
[TBL] [Abstract][Full Text] [Related]
4. Association of Preoperative Serum Levels of CEA and CA15-3 with Molecular Subtypes of Breast Cancer.
Zhao W; Li X; Wang W; Chen B; Wang L; Zhang N; Wang Z; Yang Q
Dis Markers; 2021; 2021():5529106. PubMed ID: 34621407
[TBL] [Abstract][Full Text] [Related]
5. Nipple discharge of CA15-3, CA125, CEA and TSGF as a new biomarker panel for breast cancer.
Wang G; Qin Y; Zhang J; Zhao J; Liang Y; Zhang Z; Qin M; Sun Y
Int J Mol Sci; 2014 May; 15(6):9546-65. PubMed ID: 24879526
[TBL] [Abstract][Full Text] [Related]
6. Maternal serum Ca125 and Ca15-3 antigen levels in normal and pathological pregnancy.
Bon GG; Kenemans P; Verstraeten AA; Go S; Philipi PA; van Kamp GJ; van Geijn HP; van Vugt JM
Fetal Diagn Ther; 2001; 16(3):166-72. PubMed ID: 11316933
[TBL] [Abstract][Full Text] [Related]
7. Increased production of the soluble tumor-associated antigens CA19-9, CA125, and CA15-3 in rheumatoid arthritis: potential adhesion molecules in synovial inflammation?
Szekanecz E; Sándor Z; Antal-Szalmás P; Soós L; Lakos G; Besenyei T; Szentpétery A; Simkovics E; Szántó J; Kiss E; Koch AE; Szekanecz Z
Ann N Y Acad Sci; 2007 Jun; 1108():359-71. PubMed ID: 17893999
[TBL] [Abstract][Full Text] [Related]
8. Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients.
Jiang XP; Yang DC; Elliott RL; Head JF
Cancer Biother Radiopharm; 2000 Oct; 15(5):495-505. PubMed ID: 11155821
[TBL] [Abstract][Full Text] [Related]
9. Factors influencing serum CA125II levels in healthy postmenopausal women.
Pauler DK; Menon U; McIntosh M; Symecko HL; Skates SJ; Jacobs IJ
Cancer Epidemiol Biomarkers Prev; 2001 May; 10(5):489-93. PubMed ID: 11352859
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer.
Bian J; Li B; Kou XJ; Liu TZ; Ming L
Asian Pac J Cancer Prev; 2013; 14(11):6241-3. PubMed ID: 24377511
[TBL] [Abstract][Full Text] [Related]
11. Microchip fluorescence-enhanced immunoaasay for simultaneous quantification of multiple tumor markers.
Shi M; Zhao S; Huang Y; Liu YM; Ye F
J Chromatogr B Analyt Technol Biomed Life Sci; 2011 Sep; 879(26):2840-4. PubMed ID: 21873123
[TBL] [Abstract][Full Text] [Related]
12. Clinical Use and Optimal Cutoff Value of Ca15-3 in Evaluation of Adnexal Mass: Retrospective Cohort Study and Review of the Literature.
Sagi-Dain L; Lavie O; Auslander R; Sagi S
Am J Clin Oncol; 2018 Sep; 41(9):838-844. PubMed ID: 28338481
[TBL] [Abstract][Full Text] [Related]
13. Pre-operative discrimination between benign and malignant ovarian tumors using a combination of CA125 and CA15.3 serum assays.
Yedema C; Massuger L; Hilgers J; Servaas J; Poels L; Thomas C; Kenemans P
Int J Cancer Suppl; 1988; 3():61-7. PubMed ID: 3209301
[TBL] [Abstract][Full Text] [Related]
14. Expression and significance of ER, PR, VEGF, CA15-3, CA125 and CEA in judging the prognosis of breast cancer.
Zhang SJ; Hu Y; Qian HL; Jiao SC; Liu ZF; Tao HT; Han L
Asian Pac J Cancer Prev; 2013; 14(6):3937-40. PubMed ID: 23886210
[TBL] [Abstract][Full Text] [Related]
15. Leukocyte alkaline phosphatase, CA15-3, CA125, and CEA in cancer patients.
Walach N; Gur Y
Tumori; 1998; 84(3):360-3. PubMed ID: 9678617
[TBL] [Abstract][Full Text] [Related]
16. Anti-CA15.3 and Anti-CA125 Antibodies and Ovarian Cancer Risk: Results from the EPIC Cohort.
Cramer DW; Fichorova RN; Terry KL; Yamamoto H; Vitonis AF; Ardanaz E; Aune D; Boeing H; Brändstedt J; Boutron-Ruault MC; Chirlaque MD; Dorronsoro M; Dossus L; Duell EJ; Gram IT; Gunter M; Hansen L; Idahl A; Johnson T; Khaw KT; Krogh V; Kvaskoff M; Mattiello A; Matullo G; Merritt MA; Nodin B; Orfanos P; Onland-Moret NC; Palli D; Peppa E; Quirós JR; Sánchez-Perez MJ; Severi G; Tjønneland A; Travis RC; Trichopoulou A; Tumino R; Weiderpass E; Fortner RT; Kaaks R
Cancer Epidemiol Biomarkers Prev; 2018 Jul; 27(7):790-804. PubMed ID: 29661801
[No Abstract] [Full Text] [Related]
17. Serum CA125 elevation and risk of clinical detection of cancer in asymptomatic postmenopausal women.
Jeyarajah AR; Ind TE; Skates S; Oram DH; Jacobs IJ
Cancer; 1999 May; 85(9):2068-72. PubMed ID: 10223249
[TBL] [Abstract][Full Text] [Related]
18. Clinical value of CYFRA21-1, NSE, CA15-3, CA19-9 and CA125 assay in the elderly patients with pleural effusions.
Li CS; Cheng BC; Ge W; Gao JF
Int J Clin Pract; 2007 Mar; 61(3):444-8. PubMed ID: 17313612
[TBL] [Abstract][Full Text] [Related]
19. Relationships among serum CA15-3 tumor marker, TNM staging, and estrogen and progesterone receptor expression in benign and malignant breast lesions.
Atoum M; Nimer N; Abdeldayem S; Nasr H
Asian Pac J Cancer Prev; 2012; 13(3):857-60. PubMed ID: 22631661
[TBL] [Abstract][Full Text] [Related]
20. [1959-1999: from serum markers to 18-FDG in oncology. The experience of the René-Huguenin Center].
Pecking AP; Mechelany-Corone C; Pichon MF
Pathol Biol (Paris); 2000 Nov; 48(9):819-24. PubMed ID: 11141917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
